EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate

EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer - VJOncology Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...

At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.

🎥 Watch: buff.ly/vLWxnoe

#BCSM #CTSM #TrialUpdate #Oncology

At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.

Click here to watch:

🎥 buff.ly/Ut0Ne7p

#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

Metastatic breast cancer updates at ESMO 2025 - VJOncology Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...

🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.

Watch here ➡️ buff.ly/E4FLjXD

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease

🎥 buff.ly/dLhijGf

#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25

DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer - VJOncology Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...

Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.

💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC

🎥 buff.ly/r3AwOkw

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social

Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.

Watch here:

👉 buff.ly/6GUNfkY 👈

#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky

The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉

We recently had the pleasure of speaking to Helen Parry to find out more about the study:

🎥 buff.ly/j1K0VV8

#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc

🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:

👉 buff.ly/paPH5vx 👈

#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky

FORAGER-1: dose optimization of LY3866288 in FGFR3-altered tumors - VJOncology Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...

Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors

🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure

🎥 buff.ly/ozWqgdG

#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25

EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer - VJOncology Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...

Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.

💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk

#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25

In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.

Click to watch:

👉 buff.ly/RVZjPoG 👈

#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky

COSMIC-313: transcriptomic predictors of metastatic sites in RCC - VJOncology Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, discusses a post-hoc transcriptomic analysis from...

Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25

🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT

🎥 Watch: buff.ly/dIMvnoC

@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe

MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer - VJOncology Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the MonarchE trial (NCT03155997) evaluating the prognostic and predictive value...

At #ESMO25, Shigehira Saji shares new MonarchE data on Ki-67 as a biomarker in HR+/HER2– high-risk #BreastCancer:

📊 High Ki-67 = ↑ recurrence risk
💊 Abemaciclib + ET effective across all Ki-67 subgroups
✅ Broad benefit, regardless of Ki-67 change

🎥 Watch: buff.ly/F1mziDY

#BCSM #CTSM #TrialUpdate

PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC - VJOncology Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Phase III PSMAddition trial (NCT04720157), which...

At #ESMO25, Scott Tagawa, MD, MS, FACP, discusses the Phase III PSMAddition trial in PSMA-positive mHSPC:

💥 Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI improved rPFS
📈 OS trend & manageable safety
✅ No major QoL impact

🎥 Watch: buff.ly/vSBfVPS

@myesmo.bsky.social #PCSM #UroOnc #UroSoMe #RadOnc #CTSM

We recently spoke with Karthik Ramasamy, who shared insight into the DREAMM-9 trial, aimed at optimizing the dose of belantamab mafodotin for the treatment of transplant-ineligible newly diagnosed #MultipleMyeloma.

Watch here: 👉 buff.ly/szIDc29

#Myeloma #MMSM #HemOnc #CTSM #TrialUpdate #MedSky

Want to hear findings from the EPCORE NHL-2 trial evaluating epcoritamab plus intensive chemo for patients with R/R #DLBCL eligible for autoSCT?

Watch our interview with Marek Trněný of @charlesuni.cuni.cz from #SOHO2025:

👉 buff.ly/GHh6dYG 👈

#LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky

At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.

Watch the interview here:

👉 buff.ly/UvDvXD3 👈

#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky

In an interview from #IMS25, Charlotte Pawlyn of @icr.ac.uk outlines ongoing UK-based clinical trials in #MultipleMyeloma, namely the FiTNESS and iFit trials.

Click here to learn more:

👉 buff.ly/3qAkNKA

#MMSM #HemOnc #CTSM #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

Watch our interview from #IMS25 with Larry Anderson to hear about the updated safety and efficacy data from the randomized Phase III AURIGA study.🩸

Click here:

🎥 buff.ly/TclKlrd

#CTSM #TrialUpdate #MMsm #Myeloma #HemOnc #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:

👉 buff.ly/rBWUBYh 👈

#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky

ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more - VJOncology Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...

⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:

🎥 buff.ly/0IeuM2Z

@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc

PROMISE: CE/BZA in postmenopausal, ER+ ductal carcinoma in situ - VJOncology Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the Phase II PROMISE study (NCT02694809), which assesses...

⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS:

🎥 buff.ly/FJvSAAR

@ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc

KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...

⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc

Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸

Watch now:

🎥 buff.ly/zBD1MpN

#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc

It's always a pleasure to catch up with Hermann Einsele!😊

At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸

Click here to watch the interview:

👉 buff.ly/Bc1gG2R 👈

#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc

RAISN: indocyanine green-guided lymph node dissection in testicular cancer - VJOncology Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy...

⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use:

🎥 buff.ly/kF09jHH

#EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm

Tailoring endocrine therapy: risk-based strategies and symptom management in HR+ breast cancer - VJOncology Michael Gnant, MD, FACS, Medical University of Vienna, reviews four key studies on long-term endocrine therapy in premenopausal HR+ breast...

⭐ Michael Gnant, MD, FACS, reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms:

🎥 buff.ly/hfp5orD

@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #CTSM #TrialUpdate

🎥 Ranjit Nair of @mdanderson.bsky.social shares the promising results of a Phase I study evaluating surovatamig (AZD0486), a CD19-targeting bispecific T-cell engager, in patients with R/R #NonHodgkinLymphoma:

🎥 👉 buff.ly/k5zLkkg

#SOHO2025 #LYMsm #Lymphoma #CTSM @societyofhemonc.bsky.social